Cargando…

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()

Glioblastoma (GBM) with oligodendroglioma component (GBMO) is a newly described GBM subtype in the 2007 World Health Organization classification. However, its biological and genetic characteristics are largely unknown. We investigated the clinicopathological and molecular features of 34 GBMOs and co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Myung, Jae Kyung, Cho, Hwa jin, Kim, Hanna, Park, Chul-Kee, Lee, Se Hoon, Choi, Seung Hong, Park, Peom, Yoon, Jung Min, Park, Sung-Hye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311043/ https://www.ncbi.nlm.nih.gov/pubmed/25500080 http://dx.doi.org/10.1016/j.tranon.2014.10.002

Ejemplares similares

Alpha Internexin Expression Related with Molecular Characteristics in Adult Glioblastoma and Oligodendroglioma
por: Suh, Ja Hee, et al.
Publicado: (2013)

Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation
por: Kim, Se-Hyuk, et al.
Publicado: (2018)

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
por: Yang, Pei, et al.
Publicado: (2015)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2020)

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
por: Chai, Ruichao, et al.
Publicado: (2021)

BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients
por: Cho, Hye Rim, et al.
Publicado: (2017)

Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
por: Mareike, Müller, et al.
Publicado: (2021)

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
por: Incekara, Fatih, et al.
Publicado: (2020)

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
por: Radke, Josefine, et al.
Publicado: (2019)

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
por: Marchi, Francesco, et al.
Publicado: (2020)

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival
por: Chaurasia, Ajay, et al.
Publicado: (2016)

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)

The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma
por: Incekara, Fatih, et al.
Publicado: (2020)

Validation of MRI-Based Models to Predict MGMT Promoter Methylation in Gliomas: BraTS 2021 Radiogenomics Challenge
por: Kim, Byung-Hoon, et al.
Publicado: (2022)

MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Radiological imaging features of glioblastoma with oligodendroglioma component: a comparison with conventional glioblastoma
por: Kanoto, Masafumi, et al.
Publicado: (2016)

A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma
por: Wang, Wen, et al.
Publicado: (2016)

Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: application of DSC perfusion MR imaging
por: Cho, Hye Rim, et al.
Publicado: (2016)

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
por: Teske, Nico, et al.
Publicado: (2021)

The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents
por: Kurdi, Maher, et al.
Publicado: (2021)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

MGMT promoter methylation in Peruvian patients with glioblastoma
por: Belmar-Lopez, Carolina, et al.
Publicado: (2018)

The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma
por: Hsu, Chih-Yi, et al.
Publicado: (2017)

MGMT and Whole-Genome DNA Methylation Impacts on Diagnosis, Prognosis and Therapy of Glioblastoma Multiforme
por: Della Monica, Rosa, et al.
Publicado: (2022)

An evaluation of MGMT promoter methylation within the methylation subclasses of glioblastoma
por: Alnahhas, Iyad, et al.
Publicado: (2020)

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
por: Combs, Stephanie E, et al.
Publicado: (2011)

Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma
por: Schiffgens, Salveena, et al.
Publicado: (2016)

MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?
por: Hau, Peter, et al.
Publicado: (2007)

Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients
por: Giunco, S., et al.
Publicado: (2023)

Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas
por: Park, Chul-Kee, et al.
Publicado: (2015)

Immunohistochemical Expression of PD-L1 and IDH1 with Detection of MGMT Promoter Methylation in Astrocytoma
por: Hareedy, Amal Ahmed, et al.
Publicado: (2022)

Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma
por: Gwak, Ho-Shin, et al.
Publicado: (2013)

Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted
por: Ballester, Leomar Y., et al.
Publicado: (2018)

Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients
por: Ye, Ningrong, et al.
Publicado: (2019)

Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
por: Thon, Niklas, et al.
Publicado: (2013)

Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma
por: Sasaki, Takahiro, et al.
Publicado: (2019)

ADC, D, f dataset calculated through the simplified IVIM model, with MGMT promoter methylation, age, and ECOG, in 38 patients with wildtype IDH glioblastoma
por: Maralani, Pejman Jabehdar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b3jmdi1ubj1jj9ms8f0e35gl1m